ESR1 and breast carcinoma: Novel technologies, including high-throughput sequencing and microarray, have enabled a better understanding of ER regulatory mechanisms (13), and chromatin immunoprecipitation sequencing has been used to demonstrate that the ER binding sites are heterogeneous in human breast cancer cell lines and tissues (14,15).